Pharmaceutical industry in Switzerland

As A Breakthrough Drug For The Expansive Osteoporosis Market, Bogutai® (Teriparatide Injection) Has Been Officially Approved By The China National Medical Products Administration (NMPA)

Retrieved on: 
Tuesday, January 30, 2024
Woman, Patient, Fracture, Partnership, Diagnosis, RMB, Pharmaceutical industry in Switzerland, Investment, Osteoporosis, Ageing, NMPA

BOGUTAI® represents the Group's strategic response to the burgeoning osteoporosis market, both globally and in China.

Key Points: 
  • BOGUTAI® represents the Group's strategic response to the burgeoning osteoporosis market, both globally and in China.
  • Approximately 200 million individuals worldwide suffer from osteoporosis, with China accounting for a substantial portion of this figure.
  • The "Primary Osteoporosis Diagnosis and Treatment Guideline (2022)" reveals that nearly 90 million people in China have osteoporosis, with the number expected to rise due to an aging population.
  • The medical expenses for major osteoporosis fractures in China are projected to reach a staggering RMB 132 billion by 2035 and rise to RMB 163 billion by 2050.

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Other Science, Science, Safety, D, Pharmaceutical industry in Switzerland, Therapy, TED, IND, Investment, Patient, Neonatal Fc receptor, LDL, Conditional sentence, Pharmacokinetics, Half-life, Immunoglobulin G, Intravenous therapy, Pharmaceutical industry, Management, Viridian

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the third quarter ended September 30, 2023.

Key Points: 
  • Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the third quarter ended September 30, 2023.
  • The ongoing THRIVE Phase 3 clinical trial of VRDN-001 in patients with active TED continues to enroll patients with topline results expected in mid-2024.
  • Net Loss: The company’s net loss was $47.7 million for the third quarter of 2023, compared with $28.9 million for the same period last year.
  • Viridian will not be hosting a conference call to discuss its third quarter financial results.

Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease

Retrieved on: 
Thursday, October 26, 2023
Health, Medical Devices, General Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Graves' ophthalmopathy, Therapy, Patient, Pharmaceutical industry in Switzerland, TED, Pharmaceutical industry, Viridian

As part of the agreement, Ypsomed will customize and supply YpsoMate 2.25 patient-administered delivery devices to support Viridian’s development of investigational subcutaneous therapy candidates for the treatment of thyroid eye disease (TED).

Key Points: 
  • As part of the agreement, Ypsomed will customize and supply YpsoMate 2.25 patient-administered delivery devices to support Viridian’s development of investigational subcutaneous therapy candidates for the treatment of thyroid eye disease (TED).
  • “Developing a subcutaneous therapy is an essential part of our vision to offer the most comprehensive set of therapeutic options to the TED community.
  • “Thus, it’s critical that we continue to improve our therapy by packaging it in a delivery device that is as convenient and user-friendly as possible.
  • We engaged in a rigorous selection process and concluded that, based on its strong track record of drug-device combination approvals in multiple disease areas, Ypsomed is the ideal partner to supply such a device.

Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors

Retrieved on: 
Monday, October 2, 2023
CO, University, Paul, Pharmaceutical industry in Switzerland, Abbott Laboratories, MBA, OSA, Doctor of Philosophy, MS, Capital, MD, Carnegie Mellon University, Boehringer Ingelheim, Growth, Merck, Pharmaceutical Research and Manufacturers of America, Rosy, Chemical engineering, Obstructive sleep apnea, Margot Fonteyn, Free University of Brussels (1834–1969), Pharmaceutical industry, Amylyx Pharmaceuticals

CAMBRIDGE, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, today announced the appointment of Paul Fonteyne, MS, MBA, to its Board of Directors as an Independent Director.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, today announced the appointment of Paul Fonteyne, MS, MBA, to its Board of Directors as an Independent Director.
  • Fonteyne replaces Ruoxi (Rosy) Hu, PhD, from Morningside Technology Advisory, LLC, who stepped down from the Board.
  • Paul also held commercial leadership roles at Merck and Co. Inc. for nine years and at Abbott Laboratories for eight years.
  • He holds an MS in Chemical Engineering from the University of Brussels and an MBA from Carnegie Mellon University.

Dexcom G6 Strengthens Its Position as World’s Most Connected CGM System With a New Aid Offering in Germany

Retrieved on: 
Friday, September 1, 2023
Medical Supplies, Medical Devices, Health, Diabetes, Health Technology, General Health, CGM, Dexcom, Hypoglycemia, AID, Senior, Pharmaceutical industry in Switzerland, Tandem, G6, DXCM, Defensive aids system, Ecosystem, United, Glycated hemoglobin, LATAM, Pharmaceutical industry, Diabetes Care

Our CGM systems were the first to enable industry-leading connectivity and we now link with over 60 connected partners worldwide,” said Alex Moussa, Senior Vice President and General Manager, Dexcom EMEA & LATAM.

Key Points: 
  • Our CGM systems were the first to enable industry-leading connectivity and we now link with over 60 connected partners worldwide,” said Alex Moussa, Senior Vice President and General Manager, Dexcom EMEA & LATAM.
  • By adding another AID product to its CGM ecosystem, Dexcom has both strengthened its position as the world’s most connected CGM, with the Dexcom G6, and offered yet another AID choice to those living with type 1 diabetes in Germany.
  • “At Dexcom we believe that diabetes technology should be built to celebrate and support the diabetes community.
  • To learn more about how Dexcom G6 offers the widest range of AID solutions for users and HCPs, visit Dexcom.com.

Dexcom G6 Strengthens Its Position as World’s Most Connected CGM System

Retrieved on: 
Wednesday, June 21, 2023
Apps, Applications, Technology, Mobile, Wireless, Medical Devices, Diabetes, Health Technology, Software, Biometrics, Health, CGM, Dexcom, Hypoglycemia, AID, Pharmaceutical industry in Switzerland, Diabetes Care, Tandem, G6, DXCM, Defensive aids system, Ecosystem, United, Glycated hemoglobin, Pharmaceutical industry

“For over a decade, Dexcom has been the sensor of choice for the development of AID systems.

Key Points: 
  • “For over a decade, Dexcom has been the sensor of choice for the development of AID systems.
  • Our CGM systems were the first to enable industry-leading connectivity and we now link with over 60 connected partners worldwide,” said Teri Lawver, Executive Vice President, Chief Commercial Officer at Dexcom.
  • By adding another AID product to its CGM ecosystem, Dexcom has both strengthened its position as the world’s most connected CGM, with the Dexcom G6, and offered yet another AID choice to those living with type 1 diabetes in the U.K.
    “At Dexcom we believe that diabetes technology should be built to celebrate and support the diabetes community.
  • To learn more about how Dexcom G6 offers the widest range of AID solutions for users and HCPs, visit Dexcom.com .

U.S. FDA Clears Abbott's FreeStyle Libre® 2 and FreeStyle Libre® 3 Sensors for Integration with Automated Insulin Delivery Systems

Retrieved on: 
Monday, March 6, 2023
Insulin, NYSE, Tandem, Loop, Woman, Regulation of tobacco by the U.S. Food and Drug Administration, GlySens ICGM, FreeStyle, Food, Continuous glucose monitor, Diabetes, FDA, United, AID, CGM, Medical device, Dietary supplement, Fine chemical, Pharmaceutical industry, Pharmaceutical industry in Switzerland

AID systems help people manage daily diabetes care by automatically adjusting and administering the insulin delivered by an insulin pump based on real-time glucose data from their FreeStyle Libre 2 or FreeStyle Libre 3 sensors.

Key Points: 
  • AID systems help people manage daily diabetes care by automatically adjusting and administering the insulin delivered by an insulin pump based on real-time glucose data from their FreeStyle Libre 2 or FreeStyle Libre 3 sensors.
  • Abbott is working with leading insulin pump manufacturers to integrate their systems with the FreeStyle Libre 2 and FreeStyle Libre 3 sensors as soon as possible.
  • The modified FreeStyle Libre 2 and FreeStyle Libre 3 sensors will be available in the U.S. later this year.
  • Over time, the modified sensors will replace the current FreeStyle Libre 2 and FreeStyle Libre 3 sensors available today in the U.S.

Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative

Retrieved on: 
Tuesday, January 31, 2023
Biotechnology, Diabetes, Other Health, Health, Pharmaceutical, FDA, Insulin lispro, Insulin, Pharmaceutical industry in Switzerland, Pharmaceutical industry, Civica

Civica, Inc. (Civica, Civica Rx) today announced the selection of Ypsomed AG as the manufacturer and supplier of insulin dosing injector pens for Civica’s affordable insulins.

Key Points: 
  • Civica, Inc. (Civica, Civica Rx) today announced the selection of Ypsomed AG as the manufacturer and supplier of insulin dosing injector pens for Civica’s affordable insulins.
  • To ensure redundancy of supply, Ypsomed will provide injector dosing pens from their two manufacturing facilities in Switzerland and Germany.
  • “As a renowned injection device specialist with over 35 years’ experience, Ypsomed will help Civica make self-administered care more affordable for Americans living with diabetes,” said Ned McCoy, President and Chief Executive Officer of Civica.
  • Contingent on FDA approval, Civica anticipates that its insulins will be available for purchase beginning as soon as 2024.

Spark Therapeutics to Invest $575M in New 500k Square Foot State-of-the-Art Gene Therapy Innovation Center on Drexel’s University City Campus

Retrieved on: 
Friday, December 17, 2021
Therapy, Solution, Spark Therapeutics, Hospital, Lists of diseases, Glycogen storage disease, School district, RO, Pharmaceutical industry in Switzerland, CHF, Heart, ROG, FDA, Ecosystem, Growth, List, Severe cognitive impairment, Infection, Faculty, College, GLOBE, Joint Medical Service (Germany), Partnership, Roche, Neurodegeneration, Drexel, Science, Research, Wallace H. Coulter, DNA, Investment, Student, Ophthalmology, Employment, DJSI, Hoffmann-La Roche, Genentech, Byrdine F. Lewis College of Nursing and Health Professions, Essential medicines, Brandywine Realty Trust, Outline of health sciences, Chestnut Street (Philadelphia), World, Environment, Drexel University, Dow Jones, University, Central nervous system, Haemophilia, Pharmaceutical industry, Fine chemical, Spark, Chugai Pharmaceutical Co.

PHILADELPHIA, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced plans to invest an initial $575M in the creation of a new, state-of-the-art gene therapy innovation center on Drexel University’s campus in the heart of Philadelphia’s University City neighborhood. Through a 99-year ground lease of Drexel University’s F Lot, the new center will be located at the intersection of 30th and Chestnut Streets and will create opportunities for collaboration with Drexel University and Philadelphia’s booming life sciences community. Terms of the ground lease, including financial terms, were not disclosed.

Key Points: 
  • Sparks gene therapy innovation center creates endless opportunities for collaboration, talent development and research investment, and were proud to make a long-term commitment to the city and add Philadelphia to the Roche map.
  • We are proud to partner with Spark Therapeutics in advancing life sciences research and innovation in University City, said John Fry, president, Drexel University.
  • Construction of Sparks new gene therapy innovation center is anticipated to begin in the fourth quarter of 2022.
  • Founded in 2013, Spark Therapeutics is the first company in the U.S. to receive FDA approval of a gene therapy for a genetic disease.

Roche announces collaboration with Ibex Medical Analytics to develop artificial intelligence-based digital pathology applications for improved patient care

Retrieved on: 
Monday, October 18, 2021
ROG, Pharmaceutical industry in Switzerland, World, Central nervous system, Acceleration, DJSI, Dow Jones, Marie Cassidy, CE, RUO, Cancer, CHF, Digital, Pathology, Joint Medical Service (Germany), Prostate, Algorithm, Hoffmann-La Roche, Breast, Laboratory, AI, RO, Infection, Workflow, Efficiency, FDA, Artificial intelligence, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, List, CEO, Immunotherapy, Essential medicines, Software, Genentech, Research, Ophthalmology, Medical imaging, Fine chemical

Through this alliance, customers using Roche Digital Pathology will gain access to Ibex's innovative tools, such as algorithms that analyse prostate and breast biopsies, in addition to the AI tools already provided by Roche.

Key Points: 
  • Through this alliance, customers using Roche Digital Pathology will gain access to Ibex's innovative tools, such as algorithms that analyse prostate and breast biopsies, in addition to the AI tools already provided by Roche.
  • "Digital pathology provides the capability to introduce new, innovative ways for laboratories to improve quality and efficiency of cancer diagnosis.
  • Together with Roche, we look forward to transforming pathology by delivering powerful AI-based tools to the fingertips of pathologists," said Joseph Mossel, CEO and Co-founder of Ibex Medical Analytics.
  • Roche offers two deployment options for its uPath software: an on-premise solution and a cloud solution, marketed as NAVIFY Digital Pathology.